title: XRCC1 polymorphisms are associated with cervical cancer risk and response to chemotherapy: a systematic review and meta-analysis.
abstract: BACKGROUND
  Functional single nucleotide polymorphisms of x-ray repair cross-complementing protein 1 (XRCC1) have been suspected to contribute to uterine cervical cancer risk for a long time; however, most previous case-control studies were small sized and biased. Additionally, recent studies suggested that XRCC1 polymorphisms could be a biomarker of response to platinum-based chemotherapy.
  
  
  METHODS
  A comprehensive search was conducted to retrieve eligible studies and odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated to measure association strength.
  
  
  RESULTS
  A total of 13 studies were identified and analyzed. We found that the Arg194Trp polymorphism (Trp vs. Arg, OR=1.342, 95% CI: 1.176) was associated with increased risk of cervical cancer, while no significant association was found with Arg280His (His vs. Arg, OR=1.059, 95% CI: 0.863, 1.299) or Arg399Gln (Gln vs. Arg, OR=1.144, 95% CI: 0.938, 1.394). As for response to platinum- based chemotherapy, the variant XRCC1 399Gln allele (Gln vs. Arg, OR=0.345, 95% CI: 0.163, 0.729) was linked with a poor response; however, the Arg194Trp polymorphism (TrpArg vs. ArgArg, OR=6.421, 95% CI: 1.573, 26.205) predicted a good response.
  
  
  CONCLUSIONS
  The Arg194Trp polymorphism of XRCC1 increases risk of cervical cancer; the variant 399Gln allele predicts poor response to platinum-based chemotherapy, while the Arg194Trp polymorphism indicates a good response.
authors: Department of Obstetrics and Gynecology, the First Affiliated Hospital of Jinan University, Guangzhou, China. piaoshuaicn@163.com
authors: Han-Lin
authors: HL
authors: Shuai
authors: Xin
authors: X
authors: Luo
authors: Rui-Ling
authors: RL
authors: Yan
authors: Jian
authors: J
authors: Li
authors: Dan-Liang
authors: DL
authors: Chen
mesh_terms: D000483:Alleles; D016022:Case-Control Studies; D004268:DNA-Binding Proteins / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006801:Humans; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D012306:Risk; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000235:genetics*; D000076105:X-ray Repair Cross Complementing Protein 1
chemical_list: D004268:DNA-Binding Proteins; D009944:Organoplatinum Compounds; D000076105:X-ray Repair Cross Complementing Protein 1; C000619371:XRCC1 protein, human